Clinical Trial

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a single-arm, prospective clinical study aimed at evaluating the efficacy and safety of hetrombopag in preventing chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal tumors. The study plans to enroll 40 patients with gastrointestinal tumors who develop thrombocytopenia due to chemotherapy. Patients who meet the inclusion and exclusion criteria will maintain the same treatment regimen and dosage as the previous cycle (N-1 cycle). On the day of chemotherapy in the current cycle (N cycle), they will take hetrombopag (D1) at 7.5 mg/day orally for 14 consecutive days on an empty stomach, and may eat two hours after administration, avoiding taking it with meals.
Trial Details
NCT Number NCT07492693
Lead Sponsor Changhai Hospital
Conditions Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Enrollment 40 participants
Start Date 2024-10-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-25